60 Degrees Pharmaceutical... (SXTP)
NASDAQ: SXTP
· Real-Time Price · USD
1.40
-0.04 (-2.64%)
At close: Oct 03, 2025, 3:59 PM
-2.64% (1D)
| Bid | 1.01 |
| Market Cap | 4.52M |
| Revenue (ttm) | 960.89K |
| Net Income (ttm) | -7.8M |
| EPS (ttm) | 0.08 |
| PE Ratio (ttm) | 17.5 |
| Forward PE | -0.71 |
| Analyst | Hold |
| Dividends | n/a |
| Ask | 1.8 |
| Volume | 42,547 |
| Avg. Volume (20D) | 551,603 |
| Open | 1.44 |
| Previous Close | 1.44 |
| Day's Range | 1.39 - 1.44 |
| 52-Week Range | 1.22 - 12.45 |
| Beta | 2.79 |
| Ex-Dividend Date | n/a |
About SXTP
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol SXTP
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for SXTP stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts60 Degrees Pharmaceuticals Inc. is scheduled to release its earnings on
Nov 13, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
-19.35%
60 Degrees Pharmaceuticals shares are trading lowe...
Unlock content with
Pro Subscription
2 months ago
-13.89%
SXTP stock has given up its prior gain. 60 Degrees Pharmaceuticals shares were trading higher after the company announced it will conduct a gap analysis of its existing data prior to submitting a Minor Use Minor Species designation request to the FDA for tafenoquine for the treatment of acute canine babesiosis.
